Rethinking recommendations for use of pneumococcal vaccines in adults

Clinical Infectious Diseases

Volumn 33, Issue 5, 2001, Pages 662-675

  Whitney, Cynthia G ^a   Schaffner, William ^b   Butler, Jay C ^c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; PNEUMOCOCCUS CONJUGATE VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; GUILLAIN BARRE SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPETENCE; INFECTION PREVENTION; INJECTION PAIN; PRIORITY JOURNAL; RACE DIFFERENCE; REVACCINATION; SMOKING; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION; VACCINATION;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035451131     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322676     Document Type: Article

References (123)

1. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
3. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
4. Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it
5. American College of preventive medicine practice policy statement: Adult immunizations
6. Practice guidelines for the management of community-acquired pneumonia in adults
7. Epidemiology of pneumococcal infections in the elderly
8. Invasive pneumococcal disease in Dallas County, Texas: Results from population-based surveillance in 1995
9. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
10. Epidemiology of invasive pneumococcal disease in southern California: Implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial
11. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era
12. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: Ethnic differences and opportunities for prevention
13. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population
14. Invasive pneumococcal infection in Baltimore, MD: Implications for immunization policy
15. Cigarette smoking and invasive pneumococcal disease
16. Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections
17. Prevention of pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices
18. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
19. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents
20. Outbreak of pneumonia in a long term care facility: Antecedent human parainfluenza virus I infection may predispose to bacterial pneumonia
21. Underutilization of pneumococcal vaccine in nursing homes in Washington state: Report of a serotype-specific outbreak and a survey
22. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronio-care facilities: Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996
23. Pneumococcal bacteremia in Monroe county, New York
24. State-specific prevalence of current cigarette and cigar smoking among adults: United States, 1998
25. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
26. Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
27. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: Evidence suggesting capsular transformation of the resistant strain in vivo
28. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae
29. Pneumococcal antibody levels one decade after immunization of healthy adults
30. Antibody to capsular polysaccharides of Streptococcus pneumoniae: Prevalence, persistence, and response to revaccination
31. Response of patients with Hodgkin's disease to pneumococcal vaccine
32. Persistence of pneumococcal antibodies in human subjects following vaccination
33. Streptococcus pneumoniae polysaccharide vaccine: Age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines
34. Antibody response to pneumococcal vaccine in patients with multiple myeloma
35. Pneumococcal anti-bodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination
36. Immunogenicity of pneumococcal revaccination in patients with chronic disease
37. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: Persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response
38. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
39. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults
40. Pneumococcal vaccine responses in cirrhosis and liver transplantation
41. Standardization of an opsonophagocytic assay of the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells
42. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia
43. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
44. Anti-pneumococcal antibody response in normal subjects: A meta-analysis
45. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides
46. Pneumococcal vaccine
47. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials
48. Safety of revaccination with pneumococcal polysaccharide vaccine
49. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine
50. Assessments of plasma HIV RNA and CD4 cell counts after combined Pneumovax and tetanus toxoid vaccination: No detectable increase in HIV replication 6 weeks after immunization
51. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
52. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia
53. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial
54. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus
55. Prevention of pneumococcal pneumonia by vaccination
56. Protective efficacy of pneumococcal polysaccharide vaccines
57. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial
58. Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans Administration Cooperative Study
59. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people
60. Nonspecificity of assaying for IgG to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia
61. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older
62. Pneumonia in old age: Active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study
63. Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution
64. Resolving the pneumococcal vaccine controversy: Are there alternatives to randomized clinical trials?
65. Evaluation of new vaccines for developing countries: Efficacy or effectiveness?
66. Polysaccharide pneumococcal vaccine efficacy: An evaluation of current recommendations
67. The clinical effectiveness of pneumococcal vaccine in the elderly
68. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
69. Preventing pneumococcal bacteremia in patients at risk: Results of a matched case-control study
70. Inefficacy of pneumococcal vaccine in a high-risk population
71. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease
72. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities
73. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
74. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
75. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
76. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination
77. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccine in adults and infants
78. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine
79. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides
80. Meningococcal C polysaccharide vaccine induces immune hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine
81. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers
82. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants
83. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine
84. State- and sex-specific prevalence of selected characteristics - Behavioral risk factor surveillance system, 1996 and 1997
85. Influenza and pneumococcal vaccination levels among adults aged greater than or equal to 65 years: United States
86. Use of standing orders programs to increase adult vaccination rates: Recommendations of the Advisory Committee on immunological practices
87. Use of pneumococcal polysaccharide vaccine is unwarranted in the US
88. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults
89. Effectiveness of immunization delivery methods
90. Improving pneumococcal vaccine rates: Nurse protocols versus clinical reminders
91. Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults
92. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults
93. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults
94. Immunization delivery methods: Practice recommendations
95. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population
96. Notice to readers: Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season
97. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines
98. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
99. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Results of the Northern California Kaiser Permanente Efficacy Trial
100. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease
101. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults
102. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides
103. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccines after treatment of Hodgkin's disease
104. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease
105. Pneumococcal disease: Prospects for a new generation of vaccines
106. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine
107. Pneumococcal conjugate vaccination for adults: Why it's important for children
108. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae
109. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype
110. Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes
111. PspA and PspC: Their potential for use as pneumococcal vaccines
112. The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses
113. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules
114. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae
115. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae
116. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae